Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

DISEASE CHARACTERISTICS:

Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer

Recurrent or progressive disease

Received at least 1 prior platinum-based chemotherapy regimen containing carboplatin, cisplatin, or another organoplatinum compound for primary disease

May include high-dose therapy, consolidation, or extended therapy after surgical or non-surgical assessment
No brain metastases or leptomeningeal involvement

PATIENT CHARACTERISTICS:

Age:

Not specified

Performance status:

Karnofsky 70-100%

Life expectancy:

Not specified

Hematopoietic:

Absolute neutrophil count at least 1,000/mm^3
Platelet count at least 100,000/mm^3
Hemoglobin at least 8.0 g/dL

Hepatic:

AST and ALT no greater than 2.5 times upper limit of normal
Bilirubin no greater than 1.8 mg/dL

Renal:

Creatinine no greater than 1.5 mg/dL

Cardiovascular:

LVEF greater than 50% by radionuclide ventriculogram or two-dimensional echocardiogram
No peripheral vascular disease requiring surgical management
No prior myocardial infarction
No congestive heart failure
No orthostatic hypotension
No acute ischemia or significant conduction abnormality (bifascicular block, defined as left anterior hemiblock with right bundle branch block, second or third degree AV blocks) as evidenced by electrocardiogram
No prior cerebrovascular event

Other:

No peripheral neuropathy grade 2 or greater
No other serious medical or psychiatric illness
Not pregnant
Negative pregnancy test
Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

See Disease Characteristics
No more than 2 prior regimens for recurrent disease, including 1 non-platinum containing regimen
At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered

Endocrine therapy:

At least 1 week since prior hormonal therapy directed at primary tumor
Concurrent hormone replacement therapy allowed

Radiotherapy:

Not specified

Surgery:

See Disease Characteristics
At least 2 weeks since prior major surgery